Tenax Therapeutics (TENX) Price & Analysis

Compare

575 Followers

TENX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.25 - $7.89

Previous CloseN/A

Volume25.45K

Average Volume (3M)23.88K

Market Cap

$26.92M

Enterprise Value$122.47M

Total Cash (Recent Filing)$105.46M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Nov 12, 2025

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding4,562,500

10 Day Avg. Volume22,415

30 Day Avg. Volume23,882

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap4.55

Enterprise Value/Revenue61.24K

Enterprise Value/Gross Profit122.47K

Enterprise Value/Ebitda-3.89

Forecast

1Y Price Target

$17.00

Price Target Upside187.16% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial StabilityTENX has reported $105.5 million in cash and cash equivalents, providing a cash runway through 2027.

Intellectual PropertyThe Canadian Intellectual Property Office has allowed claims in TENX’s patent application, providing protection through 2040.

Trial ProgressExtraordinary patient adherence in the ongoing Ph3 LEVEL trial with over 95% of randomized patients remaining on therapy.

Bears Say

Increased ExpensesR&D and SG&A expenses for the quarter were higher than expected, totaling $6 million each.

Trial DelaysThe timeline for the Ph3 LEVEL Study in PH-HFpEF has been delayed, with topline data now expected in the second half of 2026.

Tenax Therapeutics News

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

“We are pleased with the progress achieved in the second quarter, and remain in a strong position to...

15d ago

TENX

Tenax Therapeutics Reports Q2 2025 Financial Results

Tenax Therapeutics ( ($TENX) ) has released its Q2 earnings. Here is a breakdown of the information Tenax...

15d ago

TENX

Tenax Therapeutics trading resumes

13:44 EDT Tenax Therapeutics (TENX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

2M ago

TENX

Tenax Therapeutics trading halted, volatility trading pause

13:39 EDT Tenax Therapeutics (TENX) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

2M ago

TENX

Tenax Therapeutics Approves Officer Exculpation Amendment

Tenax Therapeutics ( ($TENX) ) has shared an announcement. On June 11, 2025, Tenax Therapeutics held its annual...

2M ago

TENX

Tenax Therapeutics Reports Increased Losses Amid Strategic Investments

Tenax Therapeutics ( ($TENX) ) has released its Q1 earnings. Here is a breakdown of the information Tenax...

3M ago

TENX

Positive Buy Rating for Tenax Therapeutics Driven by Promising Clinical Trials and Strong Financial Position

Leerink Partners analyst David Risinger reiterated a Buy rating on Tenax Therapeutics (TENX – Research Report) on May...

3M ago

TENX

Tenax Therapeutics price target lowered to $15 from $16 at Guggenheim

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Tenax Therapeutics (TENX) to $15 from $16 and...

4M ago

TENX

Tenax Therapeutics reports Q1 EPS (28c), consensus (41c)

“2025 is off to a strong start. We continued to make meaningful progress in both the ongoing LEVEL...

4M ago

TENX

Tenax Therapeutics sees cash, equivalents funding company through 2027

16:12 EDT Tenax Therapeutics (TENX) sees cash, equivalents funding company through 2027 Published first on TheFly – the...

4M ago

TENX

Tenax Therapeutics Advances Cardiopulmonary Therapies

Tenax Therapeutics ( ($TENX) ) has released its Q4 earnings. Here is a breakdown of the information Tenax...

4M ago

TENX

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

17:26 EDT Tenax Therapeutics (TENX) files to sell 4.14M shares of common stock for holders Published first on...

5M ago

TENX

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

Reports Tenax Therapeutics (TENX) reported cash and cash equivalents of $94.9 M as of December 31 . In...

5M ago

TENX

Is TENX a Buy, Before Earnings?

Tenax Therapeutics (TENX) is scheduled to report 4th quarter earnings on 03/27/2025. Regarding Q4 estimates, Wall Street analysts...

5M ago

TENX

TENX FAQ

What was Tenax Therapeutics’s price range in the past 12 months?

Tenax Therapeutics lowest stock price was $3.25 and its highest was $7.89 in the past 12 months.

What is Tenax Therapeutics’s market cap?

Tenax Therapeutics’s market cap is $26.92M.

When is Tenax Therapeutics’s upcoming earnings report date?

Tenax Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.

How were Tenax Therapeutics’s earnings last quarter?

Tenax Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.266 by -$0.004.

Is Tenax Therapeutics overvalued?

According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tenax Therapeutics pay dividends?

Tenax Therapeutics does not currently pay dividends.

What is Tenax Therapeutics’s EPS estimate?

Tenax Therapeutics’s EPS estimate is -0.31.

How many shares outstanding does Tenax Therapeutics have?

Tenax Therapeutics has 4,562,500 shares outstanding.

What happened to Tenax Therapeutics’s price movement after its last earnings report?

Tenax Therapeutics reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.266. Following the earnings report the stock price went up 0.677%.

Which hedge fund is a major shareholder of Tenax Therapeutics?

Currently, no hedge funds are holding shares in TENX

Company Description

Tenax Therapeutics

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Tenax Therapeutics (TENX) Earnings & Revenues

Historic Earnings Reports

TENX Stock 12 Month Forecast

Average Price Target

$17.00

▲(187.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.22,7.279999999999999,8.34,9.4,10.46,11.52,12.58,13.64,14.7,15.760000000000002,16.82,17.88,18.94,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.22,7.049230769230769,7.878461538461538,8.707692307692309,9.536923076923078,10.366153846153846,11.195384615384615,12.024615384615384,12.853846153846154,13.683076923076925,14.512307692307694,15.341538461538462,16.17076923076923,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.22,6.818461538461539,7.4169230769230765,8.015384615384615,8.613846153846154,9.212307692307693,9.810769230769232,10.409230769230769,11.007692307692308,11.606153846153846,12.204615384615384,12.803076923076922,13.401538461538461,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.79,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >